| Autor: |
Danese, Elisa, Montagnana, Martina, Caldwell, Michael D., Burmester, Jim K., Berg, Richard L., Drozda, Katarzyna, Huang, Min, Zhao, Li‐Zi, Cen, Han‐Jing, Gonzalez‐Conejero, Rocio, Roldan, Vanessa, Nakamura, Yusuke, Mushiroda, Taisei, Gong, Inna Y., Kim, Richard B., Raimondi, Sara, Tagetti, Angela, Giontella, Alice, Minuz, Pietro, Fava, Cristiano |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Jun2019, Vol. 105 Issue 6, p1477-1491, 15p |
| Abstrakt: |
The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta‐analysis at the individual patients level to capture the possible effect of ethnicity, gene—gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta‐analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients' data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7–10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text